INTRODUCTION
============

The use of angiotensin-converting enzyme inhibitors (ACEIs) is known to reduce myocardial infarction (MI) size and the risk for subsequent acute myocardial infarction (AMI), and to improve survival in post-MI patients with congestive heart failure and asymptomatic left ventricular (LV) systolic dysfunction \[[@b1-kjim-2014-268]-[@b3-kjim-2014-268]\]. Furthermore, the early administration of an ACEI has been shown to have additional mortality benefits in a recent clinical trial of patients with AMI \[[@b4-kjim-2014-268]\]. According to the current guidelines, ACEIs are recommended as a standard medical therapy for secondary prevention in AMI patients, irrespective of LV function \[[@b5-kjim-2014-268],[@b6-kjim-2014-268]\].

Angiotensin II type 1 receptor blockers (ARBs) also inhibit the renin-angiotensin system (RAS), in a manner that is different than ACEIs, via selective inhibition of the angiotensin II type 1 receptor \[[@b7-kjim-2014-268]\]. Losartan and valsartan, both ARBs, have been proven to be "not inferior" to captopril, an ACEI, in patients with AMI and heart failure and/or LV systolic dysfunction \[[@b8-kjim-2014-268]-[@b10-kjim-2014-268]\]. However, ARBs have not been adequately compared to ACEIs in AMI patients without heart failure and/or LV dysfunction.

By using data from a large Korean Acute Myocardial Infarction Registry (KAMIR), we attempted to determine the frequency of ARB prescription as the first choice in ACEI- and ARB-naive AMI patients. We describe the characteristics of the patients for whom ARBs are prescribed, and the clinical impact of prescribing ARBs instead of ACEIs as a first choice drug.

METHODS
=======

Study design and patient population
-----------------------------------

KAMIR is a prospective open observational multicenter on-line registry of Korean AMI patients that has been maintained through the support of the Korean Society of Circulation since November 2005. Details of the KAMIR database have been previously published \[[@b11-kjim-2014-268]\].

Between November 2005 and January 2008, 14,871 suspected AMI patients were enrolled in KAMIR at the time of admission. Baseline clinical data were available from 12,280 patients from 39 participating hospitals. Among them, 1,284 patients (10.5%) who had already received ACEIs (n = 626) or ARBs (n = 720) before hospitalization were excluded, and 7,516 of the remaining 10,996 patients received ACEIs or ARBs during hospitalization or at discharge. Of these patients, 6,906 provided 12-month follow-up data, but 124 of these patients received both ACEIs and ARBs and were thus excluded. In total, 6,781 patients who received ACEIs (n = 5,951) or ARBs (n = 830) during hospitalization and at discharge were analyzed in this study.

AMI was diagnosed on the basis of characteristic clinical presentation, serial changes on an electrocardiogram (ECG) suggesting infarction or injury, and an increase in cardiac enzymes \[[@b12-kjim-2014-268]\].

We analyzed baseline demographic characteristics, initial presentation, initial vital signs, ECG findings, laboratory test results, procedural data, and medications. Blood samples for baseline laboratory tests, except lipid measurement, were collected at admission or before percutaneous coronary intervention. Overnight fasting blood was also tested for lipid levels. The LV ejection fraction was determined using 2-dimensional echocardiography during the index hospitalization. In-hospital complications and their management were also recorded.

The 12-month major adverse cardiac events (MACEs) were defined as death and recurrent MI. During the follow-up period, follow-up data were obtained by reviewing medical records and interviewing patients by telephone. All data were recorded on an electronic web page-based case report form.

Statistical analyses
--------------------

Data are expressed as mean ± standard deviation for continuous variables and as percentages for categorical variables. Comparisons between baseline variables were assessed with a Student t test for continuous variables and a Pearson chi-square test for categorical variables. Patients were categorized into two groups: patients receiving ACEIs, and patients receiving ARBs. Since patients were not randomly assigned to ACEIs or ARBs, 1:4 propensity score (PS) matching based on their probability of using ARBs was performed to reduce the effect of treatment-selection bias and potential confounding factors in this observational study. For each patient, a PS indicating the likelihood of using ARBs during hospitalization and at discharge was calculated using a non-parsimonious multivariable logistic regression model with covariates including baseline demographic characteristics, initial presentation, initial vital signs, ECG findings, laboratory tests results, procedural data, in-hospital complications, and medications \[[@b13-kjim-2014-268]\]. Goodness of fit of the PS was evaluated using the c-statistic and the Hosmer-Lemeshow test. In the PS-matched cohort, the risk of each outcome was compared using Cox regression models. MACE and mortality were compared by Kaplan-Meier survival curves. For all analyses, a two-sided *p* \< 0.05 was considered statistically significant. Statistical analysis was performed using SAS version 9.1. (SAS Institute Inc., Cary, NC, USA).

RESULTS
=======

Baseline characteristics and use of medications before and after PS matching are shown in [Tables 1](#t1-kjim-2014-268){ref-type="table"} and [2](#t2-kjim-2014-268){ref-type="table"}, respectively. Overall, 4,241 of 6,098 patients (70%) in which both the LV ejection fraction and Killip status were available were Killip class 1 and had an LV ejection fraction ≥ 40%. Before PS matching, 12.2% of the patients were prescribed ARBs. Patients receiving ARBs were older, thinner, and more likely to have dyspnea, preinfarct angina pectoris, higher heart rate, higher Killip classes, atrial flutter/fibrillations at admission; during hospitalization, they were more likely to have hypertension, diabetes mellitus, previous congestive heart failure, LV dysfunction, higher glucose, and elevated creatinine levels. In contrast, ACEI users were more likely to be male, current smokers, and to have typical chest pain, ST-segment elevation MI, higher creatine kinase-MB levels, and ventricular tachyarrhythmias. Defibrillation/cardioversion were more frequently required among ACEIs users. Anti-platelet agents, except for aspirin and B-blockers, were more frequently prescribed for ACEI users, whereas diuretics were more frequently prescribed for ARB users. The GRACE (Global Registry of Acute Coronary Event) risk score was significantly higher for ARB users compared with ACEI users before PS matching (112.7 vs. 108.1, *p* \< 0.001). The GRACE risk score model distinguished low-risk (n = 4,361, 64.3%), intermediate-risk (n = 1,873, 27.6%), and high-risk (n = 547, 8.1%) categories of patients. ARBs were used more commonly among intermediate- or high-risk patients, whereas ACEIs were used more commonly among low-risk patients (*p* for trend \< 0.001).

After PS matching, the mean age of the 3,575 PS-matched patients was 65.7 ± 12.3 years old, and 2,439 (68.2%) were men. All baseline covariates between ACEI and ARB users were balanced after PS matching. There was no significant difference in GRACE risk score between ARB and ACEIs users (111.2 vs. 110.6, *p* = 0.623). There were no significant differences in use of ARBs or ACEIs across risk groups (*p* for trend = 0.718).

During follow-up, 229 MACEs (6.4%) including 209 deaths (5.8%) and 24 recurrent MIs (0.7%) occurred in the matched cohort ([Table 3](#t3-kjim-2014-268){ref-type="table"}). In the logistic regression model, the in-hospital mortality was significantly lower among ARB users as compared to ACEI users (1.3% vs. 3.3%; odds ratio \[OR\], 0.379; 95% confidence interval \[CI\], 0.190 to 0.756; *p* = 0.006). In the Cox proportional-hazards model, there were no significant differences between ARB and ACEI users in the 12-month MACE rates (3.4% vs. 3.7%; hazard ratio \[HR\], 0.911; 95% CI, 0.584 to 1.420; *p* = 0.680) or mortality (3.1% vs. 3.1%; HR, 1.012; 95% CI, 0.633 to 1.617; *p* = 0.960) among hospital survivors. The 12-month MACE occurrence was significantly lower in ARB users compared with ACEI users (4.6% vs. 6.9%; HR, 0.661; 95% CI, 0.457 to 0.956; *p* = 0.028). The difference between 12-month mortality rates among ARB (4.3%) and ACEI (6.2%) users was marginal (HR, 0.684; 95% CI, 0.467 to 1.002; *p* = 0.051). Kaplan-Meier survival estimates for 12-month MACE and mortality in the matched cohort are displayed in [Fig. 1](#f1-kjim-2014-268){ref-type="fig"}. The rate of 12-month MACE increased significantly in ACEI users subsequent to the acute phase of AMI during hospitalization. Among hospital survivors, there was no significant difference in 12-month MACE between ARB users and ACEI users. The examination of subgroups showed no heterogeneity in the effect of treatment on the risk for 12-month MACE and mortality ([Fig. 2](#f2-kjim-2014-268){ref-type="fig"}).

DISCUSSION
==========

In this multicenter observational study, the main findings were that ARBs were commonly used as the first therapy in AMI patients, particularly in those with high-risk features, and that ARB users had significantly lower in-hospital mortality and 12-month MACEs compared with ACEI users after PS matching.

The ARBs, theoretically, might be more efficacious than ACEIs at blocking RAS. In AMI patients with heart failure and/or LV dysfunction, the efficacy of ARBs compared to ACEIs for secondary prevention of MACEs has been tested in two large-scale randomized clinical studies (RCTs): OPTIMAAL (Optimal Trial in Myocardial Infarction with Angiotensin II antagonist Losartan) and VALIANT (Valsartan in Acute Myocardial Infarction Trial) \[[@b8-kjim-2014-268],[@b10-kjim-2014-268]\]. In OPTIMAAL, losartan was associated with a significant increase in cardiovascular mortality compared to captopril. In VALIANT, valsartan was "non-inferior" to captopril in patients with high risk for MACE after AMI. Neither of these studies revealed any statistically significant difference in the primary end-points between patients treated with ACEIs and those treated with ARBs. Therefore, ACEIs are recommended as the first choice for AMI patients with heart failure and/or LV dysfunction in the current guidelines, assigning ARBs as an alternative for ACEI-intolerant patients \[[@b5-kjim-2014-268],[@b6-kjim-2014-268]\]. However, ARBs are commonly prescribed instead of ACEIs in post-MI patients, as shown in the REACH (Reduction of Atherothrombosis for Continued Health) registry \[[@b14-kjim-2014-268]\]. Interestingly, ARBs were also used in our observational study as the first choice RAS blockade in AMI patients, particularly in patients with high-risk features.

In the present study, ARBs significantly reduced in-hospital mortality and 12-month MACE occurrence compared with ACEIs. The rate of 12-month MACE occurrence diverged during the very acute phase of AMI during hospitalization, a period of drug dose increase, with no further subsequent divergence. Although the better prognosis among ARB users may have been the result of chance, this study suggests that it would be worth conducting RCTs to compare ARBs and ACEIs as first choice RAS blockades in AMI patients without heart failure and/or LV dysfunction.

Our study differs from the previous RCTs in several aspects. First, KAMIR was an observational study including AMI patients irrespective of the presence of heart failure and/or LV systolic dysfunction. In clinical trials on the comparative effects of RAS blockers, AMI patients without heart failure and/or LV dysfunction were not included in sizable numbers. In the present analysis, 70% of patients did not have heart failure and/or LV systolic dysfunction. Second, dosages of ACEIs and ARBs used in observational studies like ours tend to be lower compared with those in RCTs. Recent clinical studies reported that the average dosages of ACEIs used after discharge were 50% of the effective dose determined by RCTs, with no significant differences in MACEs between ARBs and ACEIs at the dosages used \[[@b15-kjim-2014-268]\]. Therefore, the discrepancy in clinical outcomes between previous RCTs and our registry might be due to dosage differences. In this regard, registry data better reflect the clinical efficacy of ACEIs and ARBs in real-world practice. Third, methodological differences may have contributed to observed differences. In the present study, we excluded patients who had already received ACEIs or ARBs before hospitalization, whereas in VALIANT, 39.4% of the valsartan group and 38.5% of the captopril group received non-study ACEIs for an average of 5 days after the AMI, but before randomization \[[@b10-kjim-2014-268]\]. ACEIs are known to reduce mortality in the early post-MI period, with 85% of the benefit in the first week \[[@b16-kjim-2014-268]\]. Therefore, the early use of non-study ACEIs in VALIANT may have influenced the results. The mortality rates of ACEI-naive patients compared with those who received pre-randomization ACEIs in VALIANT have not yet been published \[[@b9-kjim-2014-268],[@b10-kjim-2014-268]\]. Finally, ethnic differences may also have contributed to the observed differences. The prescription rate of ARBs is lower in Western countries than it is in Asia \[[@b14-kjim-2014-268],[@b17-kjim-2014-268]\]. East Asians are more susceptible to the adverse side effect of coughing caused by ACEIs \[[@b18-kjim-2014-268],[@b19-kjim-2014-268]\], which may have led to a relatively rapid switch from ACEIs to ARBs in East Asia. However, whether the drug response differences are solely the result of genetic differences between Asians and Westerners is still unknown. Furthermore, it is not known whether these differences cause different clinical outcomes for Asian post-MI patients.

Our study has several potential limitations. First, KAMIR was an observational study as previously explained. Although propensity analysis was performed for a large number of confounding factors, no firm conclusion can be made about the causal relationship between ACEIs or ABRs and clinical outcomes. Second, we were unable to clarify the reasons for nonprescription of ACEIs or ARBs. In addition, the details regarding dosages and specific class of ACEIs or ARBs and the timing of use of ACEIs or ARBs after the onset of MI were not obtained from the patients or their physicians. Finally, patients who had previously experienced adverse reactions to ACEIs or ARBs might have been included in our study. Considering this, we may have underestimated the prescription rates for ACEIs or ARBs. Finally, no data were available on compliance or adherence regarding ACEIs or ARBs throughout the follow-up period. We were unable to detect how much crossover occurred between ACEI-users and ARB-users.

In conclusion, ARBs significantly reduced in-hospital mortality and 12-month MACEs compared with ACEIs in Korean AMI patients. Further RCTs are required for AMI patients without heart failure and/or LV dysfunction.

KEY MESSAGE
===========

1\. Angiotensin II type 1 receptor blockers (ARBs) were commonly used in Korean acute myocardial infarction patients, particularly those with high-risk features, as a first choice therapy.

2\. Korean ARB users had signif icantly lower in-hospital mortality and 12-month major adverse cardiac event occurrence compared with angiotensin-converting enzyme inhibitor users after propensity score matching.
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###### 

Baseline characteristics associated with the use of angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers before and after propensity score matching

  Characteristic                                                             Before PS match   After PS match                                              
  -------------------------------------------------------------------------- ----------------- ---------------- ---------- --------------- --------------- -------
  Demographic                                                                                                                                              
   Age, yr                                                                   64.5 ± 12.6       66.2 ± 12.3      \< 0.001   65.7 ± 12.3     65.8 ± 12.3     0.855
   Male sex                                                                  4,357 (73.2)      543 (65.4)       \< 0.001   1,951 (68.2)    488 (68.3)      0.986
   Height, cm                                                                163.9 ± 8.7       162.7 ± 9.3      0.001      163.0 ± 8.8     163.0 ± 9.2     0.948
   Weight, kg                                                                64.7 ± 11.4       63.6 ± 11.4      0.008      63.9 ± 11.5     63.8 ± 11.3     0.933
   Body mass index, kg/m^2^                                                  24.0 ± 3.3        23.9 ± 3.1       0.383      23.9 ± 3.2      23.9 ± 3.1      0.979
  Initial presentation                                                                                                                                     
   Pre-hospital resuscitation                                                96 (1.6)          15 (1.8)         0.680      48 (1.7)        14 (2.0)        0.607
   Typical chest pain                                                        4,976 (85.0)      664 (81.2)       0.005      2,332 (82.8)    588 (83.2)      0.822
   Dyspnea                                                                   1,344 (23.7)      225 (28.1)       0.006      695 (25.4)      183 (26.5)      0.547
   Pre-infarction angina pectoris                                            2,540 (43.3)      395 (47.7)       0.017      1,296 (45.8)    329 (46.1)      0.880
   Systolic blood pressure, mmHg                                             129.8 ± 28.1      130.8 ± 29.9     0.355      130.9 ± 29.0    131.0 ± 29.4    0.932
   Heart rate, beats/min                                                     77.3 ± 19.3       79.1 ± 20.5      0.016      78.1 ± 19.5     78.5 ± 19.8     0.639
   Killip class \> 1                                                         1,265 (22.2)      251 (30.9)       \< 0.001   722 (26.2)      202 (29.0)      0.132
  ECG on admission                                                                                                                                         
   ST elevation myocardial infarction                                        3,700 (62.2)      485 (58.4)       0.038      1,750 (61.2)    435 (60.8)      0.864
   Anterior myocardial infarction                                            2,642 (46.8)      383 (48.2)       0.462      1,326 (48.4)    328 (47.9)      0.817
   Inferior myocardial infarction                                            2,043 (36.2)      299 (37.6)       0.432      1,009 (36.8)    255 (37.2)      0.840
  Heart rhythm on admission                                                                                                                                
   Sinus rhythm                                                              5,270 (91.6)      737 (90.4)       0.275      2,557 (91.7)    634 (90.6)      0.318
   Atrial flutter/fibrillation                                               223 (3.9)         46 (5.6)         0.017      128 (4.6)       37 (5.3)        0.440
   Ventricular tachycardia/ventricular fibrillation                          28 (0.5)          3 (0.4)          0.644      11 (0.4)        3 (0.4)         0.899
  Past history                                                                                                                                             
   Previous coronary heart disease                                           660 (11.1)        104 (12.6)       0.229      330 (11.6)      85 (11.9)       0.803
   Hypertension^[a](#tfn2-kjim-2014-268){ref-type="table-fn"}^               2,587 (44.0)      447 (54.4)       \< 0.001   1,481 (52.3)    366 (51.8)      0.795
   Diabetes mellitus^[b](#tfn3-kjim-2014-268){ref-type="table-fn"}^          1,495 (25.5)      256 (31.3)       \< 0.001   801 (28.4)      206 (29.3)      0.626
   Hyperlipidemia^[c](#tfn4-kjim-2014-268){ref-type="table-fn"}^             536 (10.2)        71 (9.8)         0.728      233 (9.2)       60 (9.6)        0.763
   Current smoking                                                           2,792 (47.3)      316 (38.3)       \< 0.001   1,152 (40.6)    292 (41.1)      0.801
   Previous congestive heart failure                                         77 (1.3)          18 (2.2)         0.045      40 (1.4)        13 (1.8)        0.406
   Previous cerebrovascular disease                                          358 (6.0)         52 (6.3)         0.778      173 (6.0)       47 (6.6)        0.602
  Left ventricular ejection fraction                                         52.0 ± 13.0       50.9 ± 13.4      0.023      51.3 ± 12.6     51.1 ± 13.1     0.754
  Laboratory findings                                                                                                                                      
   Glucose, mg/dL                                                            167.0 ± 76.4      174.2 ± 87.4     0.026      170.2 ± 80.5    172.6 ± 80.8    0.489
   Creatinine, mg/dL                                                         1.09 ± 0.94       1.34 ± 1.83      \< 0.001   1.11 ± 0.91     1.18 ± 1.13     0.142
   CK-MB, ng/mL                                                              142.6 ± 241.4     122.6 ± 179.1    0.004      129.3 ± 169.4   129.1 ± 186.0   0.976
   Total cholesterol, mg/dL                                                  185.0 ± 44.0      186.3 ± 47.9     0.451      187.3 ± 45.4    186.3 ± 45.3    0.608
   Triglyceride, mg/dL                                                       129.2 ± 109.0     129.6 ± 82.4     0.929      133.0 ± 128.0   129.1 ± 80.4    0.448
   HDL-C, mg/dL                                                              45.6 ± 20.9       44.8 ± 22.0      0.381      45.2 ± 14.1     45.2 ± 23.1     0.962
   LDL-C, mg/dL                                                              119.4 ± 40.2      119.9 ± 43.4     0.726      120.5 ± 41.1    120.4 ± 43.4    0.952
  PCI at index hospitalization                                               5,090 (85.5)      711 (85.7)       0.920      2,474 (86.5)    617 (86.3)      0.883
  CABG at index hospitalization                                              84 (1.4)          14 (1.7)         0.518      44 (1.5)        10 (1.4)        0.775
  In-hospital complication                                                                                                                                 
   Cardiogenic shock                                                         379 (6.4)         51 (6.1)         0.804      168 (5.9)       42 (5.9)        1.000
   New atrial flutter/fibrillation                                           43 (0.7)          14 (1.7)         0.004      28 (1.0)        6 (0.8)         0.730
   Ventricular tachycardia/ventricular fibrillation during hospitalization   235 (3.9)         16 (1.9)         0.004      63 (2.2)        16 (2.2)        0.955
   Heart failure                                                             1,059 (17.8)      170 (20.5)       0.060      555 (19.4)      140 (19.6)      0.916
   Acute renal failure                                                       30 (0.5)          4 (0.5)          0.932      12 (0.4)        3 (0.4)         1.000
   Cerebrovascular accidents                                                 46 (0.8)          4 (0.5)          0.359      14 (0.5)        4 (0.6)         0.813
   Major bleeding                                                            14 (0.2)          4 (0.5)          0.196      10 (0.3)        2 (0.3)         0.772
  Management of in-hospital complication                                                                                                                   
   In-hospital resuscitation                                                 160 (2.7)         17 (2.0)         0.278      58 (2.0)        14 (2.0)        0.905
   Defibrillation/cardioversion                                              164 (2.8)         11 (1.3)         0.015      44 (1.5)        11 (1.5)        1.000
   Mechanical ventilator                                                     217 (3.6)         27 (3.3)         0.569      86 (3.0)        22 (3.1)        0.922

Values are presented as mean ± SD or number (%).

PS, propensity score; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II type 1 receptor blockers; ECG, electrocardiogram; CK-MB, creatine kinase-MB; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.

Defined as previously diagnosed by a physician, receiving medication to lower blood pressure.

Defined as previously diagnosed by a physician, receiving medication to lower blood glucose.

Defined as previously diagnosed by a physician, receiving lipid lowering drugs.

###### 

Medications prescribed in conjunction with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers before and after propensity score matching

  Variable                   Before PS match   After PS match                                          
  -------------------------- ----------------- ---------------- ---------- -------------- ------------ -------
  Previous medication                                                                                  
   Aspirin                   357 (6.0)         85 (10.2)        \< 0.001   231 (8.1)      62 (8.7)     0.604
   Clopidogrel               95 (1.6)          25 (3.0)         0.004      57 (2.0)       18 (2.5)     0.381
   β-Blocker                 261 (4.4)         51 (6.1)         0.023      146 (5.1)      40 (5.6)     0.598
   Lipid-lowering drug       170 (2.9)         37 (4.5)         0.012      102 (3.6)      25 (3.5)     0.928
   Calcium channel blocker   399 (6.7)         89 (10.7)        \< 0.001   236 (8.3)      58 (8.1)     0.903
   Diuretic                  152 (2.6)         30 (3.6)         0.077      92 (3.2)       23 (3.2)     1.000
   Nitrate                   158 (2.7)         30 (3.6)         0.115      81 (2.8)       23 (3.2)     0.584
  In-hospital medications                                                                              
   Aspirin                   5,908 (99.3)      823 (99.2)       0.703      2,836 (99.2)   709 (99.2)   1.000
   Clopidogrel               5,837 (98.1)      800 (96.4)       0.001      2,787 (97.4)   694 (97.1)   0.565
   β-Blocker                 5,072 (85.2)      596 (71.8)       \< 0.001   2,252 (78.7)   560 (78.3)   0.807
   Lipid-lowering drug       4,839 (81.3)      662 (79.8)       0.283      2,315 (80.9)   583 (81.5)   0.717
   Heparin                   4,795 (80.6)      671 (80.8)       0.854      2,317 (81.0)   580 (81.1)   0.949
   Calcium channel blocker   619 (10.4)        182 (21.9)       \< 0.001   394 (13.8)     119 (16.6)   0.056
   Diuretic                  1,697 (28.5)      344 (41.4)       \< 0.001   1,072 (37.5)   273 (38.2)   0.730
   Nitrate                   4,846 (81.4)      667 (80.4)       0.459      2,307 (80.7)   579 (81.0)   0.849
  Discharge medication                                                                                 
   Aspirin                   5,578 (98.2)      787 (97.3)       0.066      2,684 (98.0)   683 (97.6)   0.488
   Clopidogrel               5,343 (94.1)      732 (90.5)       \< 0.001   2,554 (93.2)   643 (91.9)   0.200
   β-Blocker                 4,597 (80.9)      557 (68.9)       \< 0.001   2,044 (74.6)   515(73.6)    0.568
   Lipid-lowering drug       4,570 (80.5)      641 (79.2)       0.407      2,202 (80.4)   560 (80.0)   0.815
   Calcium channel blocker   428 (7.5)         148 (18.3)       \< 0.001   308 (11.2)     79 (11.3)    0.976
   Diuretic                  1,136 (20.0)      264 (32.6)       \< 0.001   771 (28.1)     206 (29.4)   0.503
   Nitrate                   3,486 (61.4)      490 (60.6)       0.656      1,690 (61.7)   430 (61.4)   0.895

Values are presented as number (%).

PS, propensity score; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II type 1 receptor blockers.

###### 

Twelve-month clinical outcomes in the matched cohort

  End point                        ACEIs group (n = 2,860)   ARBs group (n = 715)   ARBs vs. ACEIs         ARBs vs. ACEIs                          
  -------------------------------- ------------------------- ---------------------- ---------------------- ---------------- ---------------------- -------
  In-hospital                      2,860                     715                                                                                   
   Death from any cause            93 (3.3)                  9 (1.3)                0.379 (0.190--0.756)   0.006                                   
    Death from cardiac cause       75 (2.6)                  8 (1.1)                0.420 (0.202--0.875)   0.021                                   
    Death from non-cardiac cause   18 (0.6)                  1 (0.1)                0.221 (0.029--1.659)   0.142                                   
  Hospital survivors               2,767                     706                                                                                   
   Death or recurrent MI           103 (3.7)                 24 (3.4)                                                       0.911 (0.584-1.420)    0.680
   Death from any cause            85 (3.1)                  22 (3.1)                                                       1.012 (0.633-1.617)    0.960
    Death from cardiac cause       61 (2.2)                  14 (2.0)                                                       0.897 (0.502-1.604)    0.715
    Death from non-cardiac cause   24 (0.9)                  8 (1.1)                                                        1.303 (0.585-2.901)    0.517
   Recurrent MI                    22 (0.8)                  2 (0.3)                                                        0.355 (0.083--1.509)   0.161
  Overall                          2,860                     715                                                                                   
   Death or recurrent MI           196 (6.9)                 33 (4.6)                                                       0.661 (0.457-0.956)    0.028
   Death from any cause            178 (6.2)                 31 (4.3)                                                       0.684 (0.467-1.002)    0.051
    Death from cardiac cause       136 (4.8)                 22 (3.1)                                                       0.636 (0.406-0.998)    0.049
    Death from non-cardiac cause   42 (1.5)                  9 (1.3)                                                        0.840 (0.409-1.725)    0.634
   Recurrent MI                    22 (0.8)                  2 (0.3)                                                        0.355 (0.084-1.510)    0.161

Values are presented as number (%).

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; OR, odds ratio; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.
